Facebook Pixel

Bone Protection Drug Approved for Patients with Advanced Cancer

By Expert HERWriter Guide Blogger
Rate This

Three out of four women diagnosed with advanced breast cancer are at high risk to develop a secondary complication known as bone metastasis or "bone mets." This occurs when cancer cells from the primary tumor relocate to the bone. In addition to breast cancer, bone metastasis occurs with lung, prostate, kidney and thyroid cancers and multiple myeloma, a blood cancer.

It's been nearly a decade since the Food and Drug Administration (FDA) has approved a targeted drug therapy for bone cancer treatment in solid tumors. The drug, Denosumab, blocks a protein that breaks down bone cells. It is currently sold by Amgen under the brand name Prolia as a treatment for osteoporosis caused by menopause.

The new use was approved based on three studies showing effectiveness in preventing fractures and skeletal problems in patients with advanced cancer. It will be marketed as Xgeva and administered using a higher dose and more frequent dosing than Prolia. Xgeva is a monoclonal antibody that targets a protein involved in cancer-related bone destruction called human RANKL. Other FDA-approved drugs for similar conditions include Zometa (zoledronic acid) and Aredia (pamidronate disodium).

Xgeva is not approved at this time for patients with multiple myeloma or other cancers of the blood. Additional clinical trials are expected to be conducted to determine whether the drug could be used for these patients in the future.

According to a news release from Amgen, more than 50 percent of cancer patients with bone metastases will experience debilitating skeletal-related events (SREs) including fractures, spinal cord compression and severe bone pain that may require surgery or radiation. Such events can profoundly disrupt a patient’s life and can cause disability and pain. Amgen puts the total economic burden of patients with bone metastases in the U.S. alone at $12.6 billion annually. The company states the use of Xgeva would result in cost offsets due to the reduced incidence of SREs and related medical costs.

Xgeva will cost $1,650 monthly. To assist patients, Amgen has launched The Xgeva First Step Coupon Program for eligible patients who need help meeting their deductible, co-insurance, and/or co-payment requirements. Under this program, eligible patients will incur no out of pocket costs for their initial Xgeva injection and pay a maximum of $25 for subsequent injections.

Amgen has also submitted marketing applications for Xgeva in the European Union, Australia, Canada and Switzerland. For more product information visit www.xgeva.com.


American Cancer Society: Bone Metastasis Detection, Diagnosis and Staging


LIVESTRONG: Bone Cancer Treatments


FDA: News Release - FDA approves Xgeva to help prevent cancer-related bone injury


Amgen: Denosumab Development Fact Sheet


Myeloma Beacon: Xgeva Receives FDA Approval For Bone Disease In Solid Tumors, But Not Multiple Myeloma


Cleveland Clinic Review: Denosumab: A New Therapy for Osteoporosis


Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy
Expert HERWriter Guide Blogger View Profile Send Message

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.

Prostate Cancer

Get Email Updates

Related Topics

Prostate Cancer Guide


Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!